Elcelyx Therapeutics

Elcelyx Therapeutics spins out NaZura BioHealth

Wednesday, September 4, 2013

Elcelyx Therapeutics has established NaZura BioHealth, a separate company focusing on development of Gut Sensory Modulators (GSM) including lead product Lovidia, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet, the company’s proprietary delayed-release formulation of metformin for the treatment of patients with type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

[Read More]